Controversies in chemotherapy of prostate cancer.

Rüdiger Heicappell

Journal: Frontiers of radiation therapy and oncology 2002;36():72-80

PMID: 11842757

Full Text on S. Karger AG, Basel, Switzerland View on PubMed

Abstract

Address: Department of Urology, Universitätsklinikum Benjamin Franklin, Freie Universität, Berlin, Germany. [email protected]

DOI: 10.1159/000061331

Link outs

Free resources

Medical:

https://medlineplus.gov/prostatecancer.html

Subscription / membership required

Full Text Sources:

https://doi.org/10.1159/000061331

MeSH Terms: Adenocarcinoma, Adrenal Cortex Hormones, Androgen Antagonists, Antigens, Neoplasm, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Clinical Trials as Topic, Docetaxel, Estramustine, Humans, Male, Mitoxantrone, Neoplasms, Hormone-Dependent, Paclitaxel, Palliative Care, Prostate-Specific Antigen, Prostatic Neoplasms, Suramin, Taxoids, Testosterone, Treatment Outcome

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.